NNC0174-0833 is a long acting medication that has been studied for management of diabetes. These trials showed a weight loss effect, so it is being studied here as a possible means of weight management treatment. The study seeks to determine the dose of NNC0174-0833, a long acting medication, which may be most effective for weight management for people suffering from overweight or obesity. This study is over a period of 26 weeks along with a 7-week follow-up period. Five doses of NNC0174-0833 will be compared against the drug liraglutide 3.0 mg and an inactive placebo.
Participants will be randomly assigned to receive one of these drugs. All participants will receive diet and physical activity counseling. Participants will inject themselves once-weekly or once-daily with study medication. The primary measure of the study will be weight change, body measurement, blood sugar measurement and safety and tolerability of the drug.
The proposed project recognizes the relationship between food insecurity and social determinants of health. By developing a strong clinic/organization linkage between specific Palmetto Health clinics and FoodShare, we will be able to determine if increasing access to fresh produce through an every other week produce box, participation in cooking classes, and clinician reinforcement improves health outcomes for patients who are identified as food insecure.
Emerging adults with obesity are at risk of developing further health problems as they progress into adulthood. There are limited interventions developed for this population, and no interventions specifically study the role of mood and positive affect on improving motivation for healthy lifestyles. Positive psychological wellbeing is linked to improved cardiometabolic risk and health via improved health behaviors and biological functioning. Given biological and psychological differences between males and females during this transition period, targeted interventions for each gender are needed. In this small pilot study, Quality of Life Therapy (QOLT), an empirically-supported and manual-guided intervention combining CBT and positive psychology techniques, will be adapted for emerging adult females with obesity. For this small pilot, we will use a sample of emerging adult females with obesity (EAO) 18-25 years to refine and test feasibility of QOLT adapted for this specific population (QOLT-EAO), with a focus on developing motivation for healthy lifestyles.
Non-Alcoholic fatty liver disease is the most common liver disease, and involves fat deposition in the liver. The fat in the liver can lead to inflammation, scarring, end stage liver disease and potential liver cancer. Some patients with fat in their liver do not see these changes, and our current understanding of why some people are not affected while others see progression of their disease is poor. We are currently in process of initiating studies to learn more about fatty liver disease, and having a database of patients at the VA medical center who are willing to participate in these studies and future studies would help both the patients learn about the new and upcoming therapies, and help the clinical investigators to quickly screen their patients and invite them to participate in their studies.
As our bodies use the sugars that we consume for energy they generate waste chemicals known as metabolites. One such group of metabolites is known as advanced glycation end products or AGEs for short. Critically apart from their production as a result of sugar breakdown, AGE levels in the body are also increased by the foods that we eat and when we do not get enough exercise. AGEs may cause many of the side effects experienced by prostate cancer survivors. This study aims to examine the effects of diet change and exercise on AGE levels in prostate cancer survivors.
The purpose of this study is to determine if giving the medicine "heparin" intravenously (through the veins) continuously for up to 14 days to subjects after a brain aneurysm has burst will help improve the chances of subjects having a good recovery after the bleed compared to subjects who get routine brain aneurysm care (standard of care). Patients who get routine care would also get heparin, but they would typically get an overall lower dose and the heparin would be injected under the skin (heparin shot) instead of in the veins.
The TRANSFORM network is focused on improving child health outcomes in SC through research on conditions of highest priority for future generations. These include conditions like asthma, autism, diabetes, obesity and early childhood outcomes. To accelerate research study recruitment activities for future projects that TRANSFORM sites may participate in, the TRANSFORM network sites will create a research recruitment registry of families interested in volunteering for research. Participants will enter their own as well as their child(ren)'s information into the electronic registry which can be used to identify people to contact for future studies.
This trial of pitavastatin will determine efficacy and safety in this high risk population, and provide evidence for clinicians to target this treatable risk factor to achieve an impact on early atherosclerosis, and potentially achieve primary prevention of adult cardiovascular disease.
We are conducting the INSIGHT COPD study because symptoms of chronic obstructive pulmonary disease (COPD) and high body mass index (BMI) overlap. There are many medications for patients with COPD, but there is little mention of weight loss as a possible treatment in current research. We are trying to find out if a lifestyle program that promotes modest weight loss and increased physical activity will improve COPD symptoms and lead to better exercise tolerance for those with a high BMI. We are also looking at the effects on shortness of breath, quality-of-life, and cardiovascular disease risk factors. The INSIGHT COPD trial is taking place at many sites across the United States including MUSC, and is planning to enroll approximately 1000 people.
TARGET-HCC is a 5-year, longitudinal, observational study of the natural history and management of patients with HCC. The study will address important clinical questions that remain unanswered in the management of HCC with a unique research registry of participants with HCC from academic and community real-world practices. TARGET-HCC is disease focused, not drug specific, which allows for continuous acquisition of real-world evidence regarding the natural history, management, and outcomes of treatment with current therapies and new treatments that may be utilized in usual clinical practice.